Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Autoimmune ocular disorders.

L V Rizzo1, S M Whitcup, R B Nussenblatt

  • 1Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|May 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact on short-lived climate forcers increases projected warming due to deforestation.

Nature communications·2018
Same author

Is age associated with the development of antibodies against botulinum toxin?

Allergologia et immunopathologia·2012
Same author

Immunopathology of ocular onchocerciasis 3. Th-2 helper T cells in the conjunctiva.

Ocular immunology and inflammation·2012
Same author

Involvement of cell adhesion molecules in the pathogenesis of experimental autoimmune uveoretinitis.

Ocular immunology and inflammation·2012
Same author

Intraocular inflammation in transgenic mice expressing a foreign antigen in their lens a preliminary report.

Ocular immunology and inflammation·2012
Same author

Association of Propionibacterium acnes endophthalmitis with HLA-DQw5.

Ocular immunology and inflammation·2012
Same journal

Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Oral administration of antigens can induce tolerance, offering a potential treatment for autoimmune diseases like uveitis. Early trials show promise for this oral tolerance therapy in treating ocular autoimmunity.

Area of Science:

  • Immunology
  • Ophthalmology
  • Mucosal Immunology

Background:

  • Oral tolerance, the immune system's unresponsiveness to orally administered antigens, has been known for years.
  • Its application in treating autoimmune diseases is a newer area of research within mucosal immunology.
  • The eye's unique immunological properties make ocular autoimmunity a particularly interesting target for novel therapies.

Purpose of the Study:

  • To investigate the potential of oral tolerance as a therapeutic strategy for uveitis.
  • To evaluate the safety and efficacy of orally administered antigens for treating ocular autoimmune conditions.

Main Methods:

  • Laboratory studies suggested feeding ocular antigens could be a safe and effective uveitis therapy.
  • Clinical application involved oral administration of retinal S-antigen to patients with uveitis.

Related Experiment Videos

Main Results:

  • Two patients with uveitis experienced successful treatment outcomes following oral administration of retinal S-antigen.
  • A phase I/II clinical trial evaluating oral tolerance for uveitis is nearing completion at the National Eye Institute.

Conclusions:

  • Oral administration of antigens, inducing oral tolerance, shows potential as a safe and effective treatment for uveitis.
  • Further clinical trials are warranted to confirm the efficacy of this approach for ocular autoimmune diseases.